Retrophin is a fully-integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. Our approach centers on our pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis, or FSGS, and RE-024 for pantothenate kinase-associated neurodegeneration, also known as PKAN. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Our R&D efforts are supported by revenues from our marketed products, Chenodal¬, Cholbam¬ and Thiola¬. Retrophin is headquartered in San Diego, CA with offices in Cambridge, MA.
- Company Name:Retrophin
(View Trends)
-
Headquarters: (View Map)San Diego, CA, United States
-
Biotechnology
-
200 - 500 employees
- 2325600 Global Rank
- 495446 United States
-
Direct64.86%
-
Search33.36%
-
Referrals1.54%
-
Social0.24%
-
Display0.00%
-
Mail0.00%
![](https://d2msby6dr6c92m.cloudfront.net/assets/similar-web-d795926c93666fae2318ea9a54f39ba58f506fd2065875b501c4f2682992c700.png)
- Ireland 39.1%
- India 29.5%
- United States 19.5%
- Zoos and Aquariums